Get started
Author

Rosemary Lord

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
2019 · Andrew R Clamp, Elizabeth C James, et al. · The Lancet · 214
PDF
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
2015 · R Paul Symonds, Charlie Gourley, et al. · The Lancet Oncology · 119
PDF
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
2019 · Martin Gore, Allan Hackshaw, et al. · Gynecologic Oncology · 111
Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
2020 · Robert D Morgan, Iain A McNeish, et al. · The Lancet Oncology · 78
The molecular genetics of chemotherapy–induced peripheral neuropathy: A systematic review and meta-analysis
2017 · J. Cliff, A.L. Jorgensen, et al. · Critical Reviews in Oncology/Hematology · 71
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903
2019 · Linda Mileshkin, Richard Edmondson, et al. · Gynecologic Oncology · 66
PDF
Adenovirus Type 9 Fiber Knob Binds to the Coxsackie B Virus-Adenovirus Receptor (CAR) with Lower Affinity than Fiber Knobs of Other CAR-Binding Adenovirus Serotypes
2001 · Ian Kirby, Rosemary Lord, et al. · Journal of Virology · 58
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
2022 · Andrew R Clamp, Elizabeth C James, et al. · The Lancet Oncology · 53
PDF
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
2021 · Susana N. Banerjee, Monica Tang, et al. · Gynecologic Oncology · 46
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).
2015 · Martin Eric Gore, Allan Hackshaw, et al. · Journal of Clinical Oncology · 37
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
2020 · Sarah P Blagden, Adrian D Cook, et al. · The Lancet Oncology · 35
PDF
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
2020 · Anna Olsson-Brown, Rosemary Lord, et al. · Endocrine Connections · 32
PDF
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
2020 · M.R. Hall, H.-M. Dehbi, et al. · Gynecologic Oncology · 28
PDF
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies
2011 · R. Lord, A. Suddle, et al. · International Journal of Clinical Practice · 27
PDF
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer
2021 · E. Frangou, G. Bertelli, et al. · Gynecologic Oncology · 23
PDF
The mutational profile of sporadic epithelial ovarian carcinoma.
2011 · S Kalamanathan, V Bates, et al. · PubMed · 19
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)
2021 · M. Friedlander, C. Benson, et al. · Gynecologic Oncology · 18
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
2024 · Robert D. Morgan, George J. Burghel, et al. · Genetics in Medicine · 17
PDF
PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.
2018 · Susana N. Banerjee, Monica Tang, et al. · Journal of Clinical Oncology · 13
Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer
2017 · L.H. Cossar, A.G. Schache, et al. · Clinical Oncology · 12
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
2022 · Mansoor Raza Mirza, Gabriel Lindahl, et al. · Cancer Research Communications · 11
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
2017 · Jose Maria Del Campo, Mansoor Raza Mirza, et al. · Journal of Clinical Oncology · 9
CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
2023 · Laurence McEvoy, Joanne Cliff, et al. · Frontiers in Pharmacology · 8
Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial—ANZGOG 0903.
2016 · Linda R. Mileshkin, Richard J Edmondson, et al. · Journal of Clinical Oncology · 8
Circca: a Randomised Double Blind Phase Ii Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer. (Cruk Grant Ref: C1256/A11416)
2014 · P. Symonds, C. Gourley, et al. · Annals of Oncology · 8
Works count: 58
Citation count: 1,171
H-index: 17
I10-index: 21
Year
Topic
Type